Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
<h4>Objective</h4> The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-D...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449172/?tool=EBI |
Search Result 1
Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Published 2023-01-01
Get full text
Article